Audrey M Sigmund1, Adam S Kittai2. 1. Division of Hematology, Department of Internal Medicine, The Ohio State University, 11th Floor Lincoln Tower and 1140D Lincoln Tower, 1800 Cannon Drive, Columbus, OH, 43210, USA. 2. Division of Hematology, Department of Internal Medicine, The Ohio State University, 11th Floor Lincoln Tower and 1140D Lincoln Tower, 1800 Cannon Drive, Columbus, OH, 43210, USA. Adam.Kittai@osumc.edu.
Abstract
PURPOSE OF REVIEW: Richter's transformation (RT) occurs when chronic (CLL) transforms into an aggressive lymphoma. Despite improvements in the treatment of CLL, prognosis for RT remains poor. Here, we review current literature of RT, with a focus on novel treatment options. RECENT FINDINGS: Efforts are underway to improve outcomes for patients with RT. While small molecule inhibitors have limited efficacy as monotherapy, recent developments combining them with chemo-immunotherapy show promise. Studies exploring the use of cellular therapies including chimeric antigen receptor T-cells and bispecific antibodies are ongoing. The current treatment paradigm for RT is to enroll these patients on a clinical trial when available, together with consultation for a consolidative allogeneic stem cell transplant. Trials investigating novel combinations and cellular therapy are ongoing. Determining predictive variables of transformation is imperative to design studies that allow for early identification and intervention for patients with RT.
PURPOSE OF REVIEW: Richter's transformation (RT) occurs when chronic (CLL) transforms into an aggressive lymphoma. Despite improvements in the treatment of CLL, prognosis for RT remains poor. Here, we review current literature of RT, with a focus on novel treatment options. RECENT FINDINGS: Efforts are underway to improve outcomes for patients with RT. While small molecule inhibitors have limited efficacy as monotherapy, recent developments combining them with chemo-immunotherapy show promise. Studies exploring the use of cellular therapies including chimeric antigen receptor T-cells and bispecific antibodies are ongoing. The current treatment paradigm for RT is to enroll these patients on a clinical trial when available, together with consultation for a consolidative allogeneic stem cell transplant. Trials investigating novel combinations and cellular therapy are ongoing. Determining predictive variables of transformation is imperative to design studies that allow for early identification and intervention for patients with RT.
Authors: Sameer A Parikh; Thomas M Habermann; Kari G Chaffee; Timothy G Call; Wei Ding; Jose F Leis; William R Macon; Susan M Schwager; Kay M Ristow; Luis F Porrata; Neil E Kay; Susan L Slager; Tait D Shanafelt Journal: Am J Hematol Date: 2015-01-30 Impact factor: 10.047
Authors: Apostolia-Maria Tsimberidou; Susan O'Brien; Issa Khouri; Francis J Giles; Hagop M Kantarjian; Richard Champlin; Sijin Wen; Kim-Anh Do; Susan C Smith; Susan Lerner; Emil J Freireich; Michael J Keating Journal: J Clin Oncol Date: 2006-05-20 Impact factor: 44.544
Authors: O Al-Sawaf; S Robrecht; J Bahlo; A M Fink; P Cramer; J V Tresckow; E Lange; M Kiehl; M Dreyling; M Ritgen; J Dürig; E Tausch; C Schneider; S Stilgenbauer; C M Wendtner; K Fischer; M Hallek; B Eichhorst Journal: Leukemia Date: 2020-03-17 Impact factor: 11.528
Authors: Sameer A Parikh; Kari G Rabe; Timothy G Call; Clive S Zent; Thomas M Habermann; Wei Ding; Jose F Leis; Susan M Schwager; Curtis A Hanson; William R Macon; Neil E Kay; Susan L Slager; Tait D Shanafelt Journal: Br J Haematol Date: 2013-07-11 Impact factor: 6.998
Authors: Yucai Wang; Marcella A Tschautscher; Kari G Rabe; Timothy G Call; Jose F Leis; Saad S Kenderian; Neil E Kay; Eli Muchtar; Daniel L Van Dyke; Amber B Koehler; Susan M Schwager; Susan L Slager; Sameer A Parikh; Wei Ding Journal: Haematologica Date: 2019-06-13 Impact factor: 9.941